| Literature DB >> 35806393 |
Maria Giovanna Rizzo1, Nicoletta Palermo1, Ugo D'Amora2, Salvatore Oddo1, Salvatore Pietro Paolo Guglielmino1, Sabrina Conoci1,3, Marta Anna Szychlinska4, Giovanna Calabrese1.
Abstract
Articular cartilage is characterized by a poor self-healing capacity due to its aneural and avascular nature. Once injured, it undergoes a series of catabolic processes which lead to its progressive degeneration and the onset of a severe chronic disease called osteoarthritis (OA). In OA, important alterations of the morpho-functional organization occur in the cartilage extracellular matrix, involving all the nearby tissues, including the subchondral bone. Osteochondral engineering, based on a perfect combination of cells, biomaterials and biomolecules, is becoming increasingly successful for the regeneration of injured cartilage and underlying subchondral bone tissue. To this end, recently, several peptides have been explored as active molecules and enrichment motifs for the functionalization of biomaterials due to their ability to be easily chemically synthesized, as well as their tunable physico-chemical features, low immunogenicity issues and functional group modeling properties. In addition, they have shown a good aptitude to penetrate into the tissue due to their small size and stability at room temperature. In particular, growth-factor-derived peptides can play multiple functions in bone and cartilage repair, exhibiting chondrogenic/osteogenic differentiation properties. Among the most studied peptides, great attention has been paid to transforming growth factor-β and bone morphogenetic protein mimetic peptides, cell-penetrating peptides, cell-binding peptides, self-assembling peptides and extracellular matrix-derived peptides. Moreover, recently, phage display technology is emerging as a powerful selection technique for obtaining functional peptides on a large scale and at a low cost. In particular, these peptides have demonstrated advantages such as high biocompatibility; the ability to be immobilized directly on chondro- and osteoinductive nanomaterials; and improving the cell attachment, differentiation, development and regeneration of osteochondral tissue. In this context, the aim of the present review was to go through the recent literature underlining the importance of studying novel functional motifs related to growth factor mimetic peptides that could be a useful tool in osteochondral repair strategies. Moreover, the review summarizes the current knowledge of the use of phage display peptides in osteochondral tissue regeneration.Entities:
Keywords: biomimetic peptides; cartilage; osteoarthritis; phage-based functional peptides; tissue engineering; tissue regeneration
Mesh:
Substances:
Year: 2022 PMID: 35806393 PMCID: PMC9266819 DOI: 10.3390/ijms23137388
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Schematic representation of peptides used in OCTE as a powerful tool to mimic the native osteochondral tissue.
Figure 2Representative scheme illustrating the molecular mechanisms of transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) signaling-derived chondro- and osteoinductive peptides through the activation of SMAD-dependent signaling to induce/promote the chondrogenesis and/or osteogenesis of MSCs.
List of the peptides involved in OCTE.
| Name | Sequence | Function | Biomaterial | Peptide Amount |
| Ref. |
|---|---|---|---|---|---|---|
| Cytomodulins | AA1-AA2-AA3…AAn (AA1 = A, N, L; AA2 = V, I; AA3 = A; AAn = Q, D, E, N) | Improve collagen I expression and promote wound healing | - | CM-1, CM2, 0.1–1 μM | Human | [ |
| Poly(lactide-co-glycolide) (PLGA) microspheres | CM-1, 200 ng/mL | Human dermal fibroblast cells (HDFs) | [ | |||
| Co-assembly peptide amphiphile (PA) | 5 or 10 mol% TGF-binding PA | Mesenchymal stem cells | [ | |||
| Chitosan (CS) | CS:peptide = 10:1 | MSCs | [ | |||
| Gelatin methacryloyl (GelMA), GelMA/hydroxyapatite (HAp) (bilayered scaffold) | TGF-β1 peptide, via covalent linking, 50–400 μg/mL | MSCs | [ | |||
| GelMA | 0.025 mM, TGF-β1-affinity peptide | Human umbilical cord mesenchymal stem cells (huMSCs) | [ | |||
| β-tricalcium phosphate (TCP)/PLGA–subchondral region. Poly(D,L-lactic acid-co-trimethylene carbonate)–cartilage region | 20 μg of TGF-β1/collagen I (1 mL, 9 mg/mL), injected into cartilage region | Rat bone-marrow-derived mesenchymal stem cells (rBMSCs) | [ | |||
| CK2.1 | - | Drives chondrogenesis and induces the formation of cartilage | - | 100 nM | C3H10T1/2 cells | [ |
| Hyaluronic acid hydrogel particles (HGPS) | HGPS (10 mg) in 10 mL PBS with CK2.1 (10 mg) | [ | ||||
| CK2.2 and CK2.3 | - | Induce osteocalcin expression and mineral deposition | - | 100 nM | [ | |
| OP-BMP-2 | NSVNSKIPKACCVPTELSAI | Promote osteogenesis | Polyethylene terephthalate | BMPs, 10–3 M | MC3T3-E1 (pre-osteoblast-like) cells | [ |
| pBMP-9 | RKVGKASSVPTKLSPISILYK | Titanium | BMP-2, 2 mg/0.5 mL in PBS | MC3T3-E1 cells | [ | |
| BMP-7 | RTVPKPSSAPTQLNAISTLYF | - | BMPs, 0.02 to 200 mg/mL | MSCs | [ | |
| B2A | B2A2-K-NS | Increases cartilage proteoglycan synthesis and chondrogenesis | - | 0–1000 ng/mL | C2C12 cells and C3H10T1/2 cells | [ |
| NLS-TAT | PKKKRKVKGRKKRRQRRRPPQ | Promotes chondrogenesis | - | 4.10 μM | Rat precartilaginous stem cells (PSCs) | [ |
| PepGen P-15 | GTPGPQGIAGQRGVV | Promotes osteoblastic activity | - | 100 µg/mL | Human periodontal ligament fibroblast cells | [ |
| Phytogene HAp (Algipore®), TCP (Bio-Base®), bovine HAp (low temperature (T)) (Bio-Oss®), bovine HAp (high T) (Osteograf®), and bovine Hp (high T) | PepGen P-15® | Human osteoblast cells | [ | |||
| Grafting materials: BioOss, OsteoGraf N-300 | PepGen P-15 | Osteoblast cells | [ | |||
| Titanium | 1 mM (dry dimethylformamide) | Preosteocyte MLO-A5 cells | [ | |||
| - | 1000 μg/mL | Human osteoblast cells | [ | |||
| Anorganic bovine-derived mineral bound to a P-15 (ABM/P-15): ABM/P-15 carboxymethyl cellulose (CMC)-hydrogel graft and ABM/P-15 particulate graft | 200 ng of P-15 per 1 g of ABM | Rabbit model | [ | |||
| Algae-derived hydroxyapatite/P-15 + 25% autologous bone | P-15 was adsorbed onto the HA surface | Pig model | [ | |||
| ABM (OsteoGrafs/N-700) and ABM/P-15 (PepGen | P-15TM, adsorbed | [ | ||||
| ABM/P-15 | - | Dog model | [ | |||
| ABM (OsteoGrafs/N-300) and ABM/P-15 | P-15™, adsorbed | Human foreskin fibroblast | [ | |||
| Peptide amphiphiles(PA) | - | Promote osteogenic differentiation | Nanofibrous PA scaffold | PA-RGDS | hMSCs | [ |
| Negatively charged PA with phosphoserine residues, negatively charged PA | [ | |||||
| OPD, 1%wt | hBMSCs | [ | ||||
| 10 mg/mL, PuraMatrix (RADA16-I) | Rabbit model | [ | ||||
| RGD | GRGDS, RGDS, YRGDS and c (RGDfk) | Improves cell adhesion and cartilage and bone tissue repair | Piranha activated borosilicate glass slides | 200 μL of 20 μM solution of RGD-TAMRA, BMP-2- | hBMSCs | [ |
| Maleimide functionalized polystyrene-block-polyethylene (PS-PEO) copolymer, spin-coated | 20 μg/mL peptide (CGRGDS, | hMSCs | [ | |||
| N-cadherin peptide | HAVDIGGGC | Promotes both early chondrogenesis of MSCs and late cartilaginous matrix production | Methacrylated hyaluronic acid | 10 mol% of methacrylates | hMSCs | [ |
| Self-assembly hydrogel | Self-assembly peptide (Ac-KLDLKLDLKLDL, KLD), N-cadherin mimetic | MSCs | [ | |||
| Poly(glycolic acid)-poly(ethylene glycol)-poly(glycolic acid)-di(but-2-yne-1,4-dithiol) (PdBT) click conjugated with either chondrogenic “GGGHAVDI” or GGGGHKSP, mixed with poly(N-isopropylacrylamide-co-glycidyl methacrylate) (P(NIPAAm-co-GMA), (bilayered hydrogel) | - | MSCs | [ | |||
| Laminin mimic peptides | IKVAV and YIGSR | Influence cartilage and bone regeneration | Maleimide functionalized PS-PEO copolymer, spin-coated | 20 μg/mL (CGRGDS, | hMSCs | [ |
| Ln2-p3 | Enhances the expression of osteogenic markers and increases ALP activity | Titanium | 23 μg/cm2 | Human osteosarcoma (HOS) cells | [ | |
| PTH 1–34 | H-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH | Stimulates osteoblast proliferation, differentiation and prevents apoptosis | - | 5 or 30 μg/kg of PTH (1–34) | Rat model | [ |
| - | PTH (1–34) in 0.9% saline at a daily dosage of 40 μg/kg body weight (BW), subcutaneously | [ | ||||
| - | PTH (1–34) in saline solution 200 μL, subcutaneously | Mouse model | [ | |||
| - | 10 μg/kg BW, daily, subcutaneously | Rabbit model | [ | |||
| OGP and OGP10–14 | YGFGG | Enhance osteoinductive potential | Bacte- | 10−9 mol/L, adsorption | Mouse model | [ |
| Collagen-mimetic peptide | GFOGER | Promotes bone regeneration and osseointegration | Titanium | 20 μg/mL in Dulbecco’s PBS | Primary bone marrow stromal cells | [ |
| DGEA | Promotes osteogenic differentiation and bone formation | Collagen Type I | 10 μg/mL | MC3T3-E1 | [ | |
| SVVYGLR | Suppresses osteoclastogenesis and contributes to bone repair at the early stage | Atelocollagen sponge | 10 μg | hMSCs | [ |
Figure 3Functional peptide selection by means of the phage display (PD) approach to functionalize biomimetic scaffolds for OCTE. (1-5) Phage Display biopanning Cyclic representation. (1) Library construction; (2) Target capturing; (3) Elution of targets-specific phages; (4) screening and analysis; (5) Phage Amplification.